You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at S&P Capital IQ Pro or S&P Capital IQ .
Destiny Pharma chairman to step down; replacement named
S&P Capital IQ Pro | Unrivaled Sector Coverage
S&P Capital IQ Pro | Powering Your Edge
Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud
Insight Weekly: Labor market struggles; solar demand remains strong; banks' deposit holdings
Destiny Pharma PLC said Nigel Rudd is stepping down as chairman and a member of its board Dec. 31.
Rudd will be replaced by Nick Rodgers, a nonexecutive director of Destiny Pharma, in the chairman role.
Brighton, U.K.-based Destiny Pharma develops and sells medicines for infectious diseases.